Induction of intrahepatic anti-tumor immunity by addressing dendritic cells and reprogramming protolerogenic non-parenchymal cell populations (B15*)

• Subject Area: Immunology
• Term: since 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 213555243

Nanovaccines accumulate in the liver typically in tolerance-promoting KC (Kupffer cells) and LSEC (sinusoi-dal liver endothelial cells). Both cell types can be reprogrammed to serve as antigen presenting cells by applying suitable adjuvants. B15N develops nanovaccines which besides dendritic cells also address and activate KC/LSEC. This approach serves to induce potent anti-tumor responses in liver and skin (metastatic melanoma). The suitability of protein nanocapsules containing peptid antigen/adjuvant and of liposomes loaded with antigen-coding mRNA/nucleic acid-based adjuvants to serve as nanovaccines will be evaluated.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1066: Nano-Dimensional Polymer Therapeutics for Tumour Therapy
• Applicant Institution: Johannes Gutenberg-Universität Mainz
• Project Heads: Privatdozent Dr. Matthias Bros; Professor Dr. Stephan Gehring; Professorin Dr. Katharina Landfester